Biblio
“Biochemical and Radiological Markers of Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 623-44, 2016.
, “Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions.”, J Alzheimers Dis, vol. 54, no. 1, pp. 307-24, 2016.
, “Biofunctionalized Silica Nanoparticles: Standards in Amyloid-β Oligomer-Based Diagnosis of Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 79-88, 2016.
, “Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.”, J Alzheimers Dis, vol. 53, no. 2, pp. 535-46, 2016.
, “Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis.”, J Alzheimers Dis, vol. 50, no. 1, pp. 161-74, 2016.
, “Blockade of the Interaction of Calcineurin with FOXO in Astrocytes Protects Against Amyloid-β-Induced Neuronal Death.”, J Alzheimers Dis, vol. 52, no. 4, pp. 1471-8, 2016.
, “Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly.”, J Alzheimers Dis, vol. 52, no. 2, pp. 561-72, 2016.
, “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.
, “Brain Amyloid-β Plays an Initiating Role in the Pathophysiological Process of the PS1V97L-Tg Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 3, pp. 1089-99, 2016.
, “Brain Atrophy of Secondary REM-Sleep Behavior Disorder in Neurodegenerative Disease.”, J Alzheimers Dis, vol. 52, no. 3, pp. 1101-9, 2016.
, “Brain Metabolism Correlates of the Free and Cued Selective Reminding Test in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 51, no. 1, pp. 27-31, 2016.
, “Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 3, pp. 1079-96, 2016.
, “Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged AβPP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1157-73, 2016.
, “Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 2, pp. 445-56, 2016.
, “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
, “A Brief Computerized Paired Associate Test for the Detection of Mild Cognitive Impairment in Community-Dwelling Older Adults.”, J Alzheimers Dis, vol. 54, no. 2, pp. 793-9, 2016.
, “Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.”, J Alzheimers Dis, vol. 54, no. 3, pp. 913-922, 2016.
, “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
, “Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.
, “Cerebral Amyloid Angiopathy (CAA)-Related Inflammation: Comparison of Inflammatory CAA and Amyloid-β-Related Angiitis.”, J Alzheimers Dis, vol. 51, no. 2, pp. 525-32, 2016.
, “Cerebral Arterial Occlusion Did Not Promote the Prevalence of Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 54, no. 1, pp. 269-74, 2016.
, “Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults.”, J Alzheimers Dis, vol. 52, no. 2, pp. 661-72, 2016.
, “Cerebral Microbleeds and Cerebrovascular Reactivity in the General Population: The EDAN Study.”, J Alzheimers Dis, vol. 53, no. 2, pp. 497-503, 2016.
, “Cerebral Small Vessel Disease and Motoric Cognitive Risk Syndrome: Results from the Kerala-Einstein Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 699-707, 2016.
, “Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 351-7, 2016.
,